|
|||||
|
|
Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression |
|
| Authors: | Yukio Hosomi Chiharu Tanai Kiyotaka Yoh Yasushi Goto Hiroshi Sakai Terufumi Kato |
| Institution: | 1. Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan;2. Division of Respirology, NTT Medical Center Tokyo, Tokyo, Japan;3. Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan;4. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan;5. Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan;6. Department of Respiratory Medicine, Kanagawa Cancer Center, Yokohama, Japan |
| Abstract: | Background: This study aimed to analyze the characteristics and outcomes of patients suffering from non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor mutations (EGFRm+) receiving gefitinib who remained clinically stable following confirmation of progressive disease (PD) using Response Evaluation Criteria in Solid Tumors (RECIST) (R-PD) and identify those who benefited from tyrosine kinase inhibitor therapy beyond PD. Research design and methods: The clinical courses of patients with EGFRm+ advanced NSCLC who received first-line gefitinib were investigated. Clinical PD (C-PD) was defined as one or more of the following: (1) symptomatic PD, (2) worsening performance status resulting from PD, (3) threat to a major organ(s), or (4) unequivocal multiorgan PD. Results: Of 529 patients, 258 experienced R-PD without C-PD. Among 258 patients, 91 received gefitinib beyond R-PD. Females were more likely to receive gefitinib beyond R-PD and exhibit a longer time from R-PD to C-PD than males (median days, 175 vs. 79.5). Survival beyond R-PD tended to be longer for elderly patients who received gefitinib beyond PD than for those who did not (median days, 458 vs. 336), but this was not the case for non-elderly patients (median days, 481 vs. 487). Conclusions: Some patients may benefit from continuation of gefitinib beyond PD. |
| Keywords: | Clinical PD disease progression EGFR gefitinib lung cancer |